The State Street Industrial Select Sector SPDR Premium Income ETF (XLII) provides income-focused exposure to the industrial sector, diversifying portfolios that are heavily weighted in technology. XLII delivers monthly income with an average yield of 13.09% and maintains reasonable net asset value (NAV) growth, supported by strong industrial sector trends. Its call spread strategy allows for more underlying asset appreciation and lower volatility compared to the broader industrial ETF XLI, though it caps upside potential. This makes XLII a recommended buy for investors seeking long-term income, NAV stability, and diversification, especially those prioritizing current income streams.
The State Street Industrial Select Sector SPDR Premium Income ETF (XLII) is featured here with Pluang's industrial sector data for context. For readers following industrials, 68 of 76 priced US industrial stocks on Pluang rose while 7 fell as of Sep 17, 2026 20:02 WIB. Notable movers include Bloom Energy at USD 283.50 with a 4.99% increase and a typical hold time of 3 days, Powell Industries at USD 185.79 up 4.55%, and FTAI Aviation Ltd at USD 197.59 rising 4.09% but with 93% sell order activity.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
